Table 3.

The relation of ever use of menopausal hormone therapy to endometrial cancer tumour grade in postmenopausal women.

	TUMOR GRADE^
	Unadjusted OR (95% CI)∫		Adjusted OR (95% CI)∫▲
Use of MHT|	2	3	2	3
Any form of MHT¶
No
Yes	0.72 (0.49–1.05)	0.48 (0.28–0.82)	0.82 (0.47–1.45)	0.52 (0.23–1.20)
Any form of oestrogens¶†∞
No
Yes	0.76 (0.52–1.13)	0.56 (0.33–0.96)	0.74 (0.42–1.32)	0.59 (0.27–1.31)
Oestrogens and Progestins¶∞‡∫Ω
No
Yes	0.89 (0.56–1.40)	0.57 (0.29–1.12)	0.89 (0.50–1.57)	0.55 (0.22–1.33)
Oestrogens with cyclic progestins¶∞∫Ω
No
Yes	0.78 (0.47–1.28)	0.41 (0.18–0.91)	0.64 (0.34–1.18)	0.23 (0.07–0.73)
Low potency vaginal Oestrogens§
No
Yes	1.00 (0.60–1.65)	1.18 (0.63–2.22)	0.91 (0.50–1.64)	1.00 (0.48–2.07)
Low potency oral oestrogens~
No
Yes	0.82 (0.54–1.26)	0.58 (0.32–1.05)	0.74 (0.45–1.20)	0.44 (0.21–0.91)

^{^}Endometrioid carcinoma grades1–3 correspond to histological differentiation: well, moderate, and poor, respectively

^|Ever use of menopausal hormone therapies are not mutually exclusive

^∫OR: odds ratio; CI: confidence interval; reference group: grade 1 endometrioid carcinoma and never users of each type of MHT

^▲All MHT exposure models adjusted for age at diagnosis, parity, age at natural menopause, body mass index, use of oral contraceptives, age at last birth, and smoking; with additional adjustments for the following models:

Any form of MHT - duration of use of oestrogens only, duration of use of progestins only, and duration of use of low potency oral oestrogens

Any form of oestrogens - duration of use of oestrogens and progestins (cyclic and/or continuous), duration of use of progestins only, and duration of use of low potency oral oestrogens

Oestrogens and Progestins (cyclic and continuous) - duration of use of oestrogens only, duration of use of progestins only, duration of use of low potency oral oestrogens; and for the analyses of cyclic addition of progestins also adjusted for duration of use of continuous use of progestins, and vice versa

Low potency vaginal and oral oestrogens - duration of use of oestrogens only, duration of use of progestins only, and duration of use of oestrogens and progestins (cyclic and/or continuous)

^¶Medium potency MHT

^†Ever use of oestrogens with or without progestins

^∞Conjugated oestrogens; oestradiol; or other synthetic

^‡Use of oestrogens and progestins, cyclic and/or continuous

^∫Cyclic progestins: added to oestrogens for less than 16 days/cycle, mostly for 10–14 days; continuous progestins: added to oestrogens for 19 or more days per cycle, mostly daily

^ΩProgesterone-like progestins (17-hydroxy-progesterone derivatives); or testosterone-like progestins (19-nor-testosterone derivatives)

^§Oestriol 0.5 mg; dienoestrol 0.5 mg; oestradiol 0.25 μg. Daily applications during initial 2–3 weeks of treatment, followed by applications twice per week

^~1–2 mg daily